Press Releases for February 10, 2016
advertisement
- Helmsley Charitable Trust Awards $3.4 Million to DreaMed Diabetes for Type 1 Diabetes Decision Support.
- Children in Europe Now Have Access to First-Of-Its-Kind Diabetes Sensing Technology – Eliminates Routine Finger Pricks.
- ViaCyte Acquires Rights to BetaLogics Assets, Expanding and Extending Industry-Leading Portfolio for Stem Cell-Derived Approaches to Type 1 Diabetes.
- U.S. Food and Drug Administration Approves Humulin® R U-500 KwikPen®.